- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06056505
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy (3DPN)
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy - A Multicentre, Randomised, Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bonn, Germany, 53127
- Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie
-
Borna, Germany, 04552
- Sana Klinikum Borna, Klinik für Urologie
-
Gronau, Germany, 48599
- St. Antonius-Hospital Gronau, Klinik für Urologie, Kinderurologie und Urologische Onkologie
-
Homburg, Germany, 66421
- Universitätsklinikum des Saarlandes - Homburg/Saar, Klinik für Urologie und Kinderurologie
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg, Klinik für Urologie, Uroonkologie, robotergestützte und fokale Therapie
-
Mainz, Germany, 55131
- Universitätsmedizin Mainz, Klinik und Poliklinik für Urologie und Kinderurologie
-
Mannheim, Germany, 68167
- Universitätsmedizin Mannheim, Klinik für Urologie und Urochirurgie
-
Wuppertal, Germany, 42283
- Helios Universitätsklinikum Wuppertal, Klinik für Urologie und Kinderurologie
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Urologie
-
Leipzig, Saxony, Germany, 4103
- Leipzig University, Department of Urology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with kidney tumours ≤ 7cm and planned robotic-assisted partial nephrectomy with the DaVinci Surgical System
- CT scan with contrast medium available
- Age ≥ 18 years
- Written informed consent
Exclusion Criteria:
- History of surgery on affected kidney (e.g., partial nephrectomy, pyeloplasty, kidney cyst deroofing, percutaneous nephrolitholapaxy, radiofrequency ablation)
- Clinical suspicion of metastases (stage cN1/cM1)
- Horseshoe kidney
- Previous malignancy with ongoing or planned nephrotoxic chemotherapy
- Multifocal kidney tumour
- Von Hippel-Lindau syndrome and other hereditary kidney cancer syndromes
- Patient is immunosuppressed (e.g., organ transplantation, leukaemia)
- Tumor thrombus in Vena renalis or Vena cava inferior
- Severe cognitive impairment
- Pregnancy or lactation or women with desire for children
- Patients under legal supervision or guardianship
- Unable to give informed consent or suspected lack of compliance
- Patients who decline data collection and storage for the main study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Partial kidney nephrectomy with aid of 3D model
The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 3D modelling of the kidney.
|
surgery for partial nephrectomy
device to perform the surgery for partial nephrectomy (not the intervention of interest)
investigational product to generate the 3D model
|
|
Active Comparator: Partial kidney nephrectomy with aid of 2D model
The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 2D modelling of the kidney.
|
surgery for partial nephrectomy
device to perform the surgery for partial nephrectomy (not the intervention of interest)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary endpoint is the console operation time measured intra-op.
Time Frame: intra-operative
|
Total console time is measured as time from starting the surgical procedure in the DaVinci console to ending the procedure in the console.
|
intra-operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-operative - PRA-D
Time Frame: Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
Quality of the Physician-Patient Relationship - Evaluation of the German Version of the Patient Reactions Assessment (PRA-D); fifteen items with seven expressions from "I do not agree at all" to "I agree completely"
|
Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
|
Pre-operative - STOA
Time Frame: Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
STATE-TRAIT-Operations-Angst (STOA) for anxiety; thirty items with four expressions from "not at all" to "very"
|
Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
|
Pre-operative - APAIS
Time Frame: Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
Amsterdam Preoperative Anxiety and Information Scale (APAIS) for anxiety; six items with five expressions from "Do not agree at all" to "strongly agree"
|
Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
|
Pre-operative - NRS
Time Frame: Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
numeric rating scale (NRS) for anxiety; numeric scale form one to ten (not afraid at all to very big anxiety)
|
Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
|
Pre-operative - Patient satisfaction questionnaire
Time Frame: Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
Patient satisfaction questionnaire regarding the informed consent process
|
Visit 1: pre-operative (between surgery consent and operation - latest 7 days after surgery consent)
|
|
Peri-operative - Hilar clamping technique
Time Frame: Visit 2: during operation
|
Hilar clamping technique (three levels: global ischemia, selective ischemia, clampless)
|
Visit 2: during operation
|
|
Peri-operative - Warm ischaemia time (WIT)
Time Frame: Visit 2: during operation
|
Warm ischaemia time (WIT) in minutes
|
Visit 2: during operation
|
|
Peri-operative - Estimated blood loss
Time Frame: Visit 2: during operation
|
Estimated blood loss in ml
|
Visit 2: during operation
|
|
Peri-operative - Number of transfusions
Time Frame: Visit 2: during operation
|
Number of transfusions
|
Visit 2: during operation
|
|
Peri-operative - Total Operative time
Time Frame: Visit 2: during operation
|
Total Operative time measured from incision to suture in minutes
|
Visit 2: during operation
|
|
Peri-operative - Number of conversions to open surgery
Time Frame: Visit 2: during operation
|
Number of conversions to open surgery
|
Visit 2: during operation
|
|
Peri-operative - Number of conversions to radical nephrectomy
Time Frame: Visit 2: during operation
|
Number of conversions to radical nephrectomy
|
Visit 2: during operation
|
|
Peri-operative - Surgeon confidence level
Time Frame: Visit 2: during operation
|
Surgeon confidence level evaluated by questionnaire survey; five questions with five expressions from "excellent" to "very bad"
|
Visit 2: during operation
|
|
Post-operative - Positive margin status
Time Frame: Visit 3: after operation up to 6 weeks
|
Positive margin status, range: R0, R1, R2, RX
|
Visit 3: after operation up to 6 weeks
|
|
Post-operative - Creatinine
Time Frame: from the end of operation until discharge (up to 6 days) and at Visit 4: 6 month after operation
|
Creatinine in µmol/l
|
from the end of operation until discharge (up to 6 days) and at Visit 4: 6 month after operation
|
|
Post-operative - eGFR
Time Frame: from the end of operation until discharge (up to 6 days) and at Visit 4: 6 month after operation
|
eGFR (CKD-EPI) in ml/min/1,73m²
|
from the end of operation until discharge (up to 6 days) and at Visit 4: 6 month after operation
|
|
Post-operative - Patient length of stay
Time Frame: from day of hospitalization (up to 7 days before operation) until the day of discharge (up to 6 days)
|
Patient length of stay in days
|
from day of hospitalization (up to 7 days before operation) until the day of discharge (up to 6 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety endpoints - Post-op complications
Time Frame: from the end of the operation until the day of discharge (up to 6 days)
|
Post-op complications categorized by Clavien-Dindo classification (grad 1 to 5)
|
from the end of the operation until the day of discharge (up to 6 days)
|
|
Safety endpoints - Number of operation- or kidney-related readmissions
Time Frame: Visit 4: six months after operation
|
Number of operation- or kidney-related readmissions
|
Visit 4: six months after operation
|
|
Safety endpoints - Number of AEs, SAEs
Time Frame: Visit 4: six months after operation
|
Number of AEs, SAEs
|
Visit 4: six months after operation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jens-Uwe Stolzenburg, Prof., Leipzig University, Department of Urology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
Other Study ID Numbers
- 3DPN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
After publication of the major results and upon reasonable request from researchers performing an individual patient data meta-analysis, individual patient data that underlie published results will be shared after de-identification.
This requires approval by the local Institutional Review Board (IRB) of the researcher requesting the data along with public registration of the metaanalysis.
Summary statistics that go beyond the scope of published material will be made available to researchers for meta-analysis upon reasonable request and if the necessary data analysis is not unduly time-consuming. Together with publication of the main results, the trial protocol in full will be made publicly available as well as the statistical analysis plan.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.